MedPath

Effect of High Dose Insulin on Infectious Complications Following Major Surgery

Not Applicable
Recruiting
Conditions
Surgical Site Infection After Major Surgery
Registration Number
NCT01528189
Lead Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Brief Summary

Despite improvements in surgical techniques and perioperative care, the high incidence of postoperative surgical site infections remains a major problem in patients undergoing major abdominal surgery (liver, pancreatic and colorectal surgery).

Using the hyperinsulinemic-normoglycemic clamp technique, i.e. continuous infusion of insulin combined with dextrose titrated to "clamp" blood glucose between 4 and 6 mmol/L, we successfully established and preserved normoglycemia during the perioperative period. Our objective of this study is to determine if the maintenance of perioperative normoglycemia by a hyperinsulinemic normoglycemic clamp reduces the rates of incisional and space/ surgical site infections following abdominal surgery (liver, pancreatic and colorectal surgery).

Detailed Description

This randomized, open-label, controlled trial will be performed in adult (\>18 years old) patients scheduled for elective open abdominal aortic aneurysm repairs and open hepatobiliary procedures including liver resections, pancreatectomies, duodenectomies, gastrojejunostomies, choledochojejunostomies and hepaticojejunostomies) at the Royal Victoria Hospital (RVH), McGill University Health Centre (MUHC), Montreal, QC, Canada.

Inclusion criteria: above 18 years old, scheduled for elective open abdominal aortic aneurysm repairs and open hepatobiliary procedures.

Exclusion criteria: inability to give consent, current wound infection, previous surgery at the same site within the preceding 30 days, allergy to insulin.

RECRUITMENT

Initial contact prior to surgery will be made by a research team member not involved in the care of the patient who will explain the research project and obtain written consent.

Consenting patients will then be randomized with the assistance of a computerized randomization system.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
460
Inclusion Criteria
  • > 18 years old
  • elective liver, pancreatic or colorectal surgery
  • ability to give informed consent
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Surgical site infectionfor 30 days after surgery

Surgical site infections will be defined according to the CDC's NNIS system.

Secondary Outcome Measures
NameTimeMethod
Surgical morbidity30 days after surgery

Surgical morbidity in the 30 days following the operation will be assessed as per Clavien score.

Trial Locations

Locations (3)

Royal Victoria Hospital, McGill University Health Centre

🇨🇦

Montreal, Quebec, Canada

Royal Victoria Hospital

🇨🇦

Montreal, Quebec, Canada

Hospital Clinico Universidad de Chile

🇨🇱

Independencia, Santiago, Chile

Royal Victoria Hospital, McGill University Health Centre
🇨🇦Montreal, Quebec, Canada
Ralph Lattermann, MD PhD
Principal Investigator
Thomas Schricker, MD PhD
Sub Investigator
George Carvalho, MD MSc
Sub Investigator
Peter Metrakos, MD
Sub Investigator
Linda Wykes, PhD
Sub Investigator
Mazen Hassanain, MD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.